



**Diastereofacial Selectivity in the Reaction of Chiral *N*-Trimethylsilyl
Imines with Ester Enolates:
Preparation of *trans* -Azetidin-2-ones in High Stereocontrolled Fashion.**

**Gianfranco Cainelli^a, Mauro Panunzio^a,
Elisa Bandini^b, Giorgio Martelli,^b Giuseppe Spunta^b**

a: Dipartimento di Chimica "G. Ciamician" Università and C.S.F.M.-C.N.R.
Via Selmi 2, 40126 Bologna Italy

b: I.Co.C.E.A.-CNR Via Gobetti, 101 40129 Bologna Italy

Abstract: Highly efficient chiral ester enolate-imine condensation, giving 3,4-disubstituted β -lactams with excellent *trans-syn* or *trans-anti* diastereoselectivity, is reported. The chiral information is included in the electrophilic partner of the condensation, nominally chiral α -, β -silyloxy- or alkoxy-*N*-trimethylsilyl-imines. The high diastereofacial selectivity is determined by the correct choice of the metal cations present in the reaction medium and the very nature of the hydroxy protecting group. By this procedure a number of azetidinones, intermediates in the synthesis of commercially interesting β -lactam antibiotics have been obtained. Fully assigned ^1H and ^{13}C NMR spectra of the so obtained azetidinones are reported.

Since its discovery by Gilman¹ in 1943, the interaction between imines and ester enolates to form β -lactams (2-azetidinones) has been one of the most versatile and useful approach to the synthesis of these compounds² and hence to the diverse families of β -lactam antibiotics³ as well as diverse important natural products for which 2-azetidinones constitute key intermediates.⁴

Following the initial Reformatsky approach, particularly developed by Kagan and Gaudemar⁵, the ester enolates-imines route to azetidinone ring received new attention from the studies by Bergbreiter and Newcomb that reported the reaction between lithium enolates of esters and imines in 1980⁶. Although the synthetic utility of the ester enolates-imines condensation has been extensively explored and the first claimed limitations (mainly fail of enolizable aldimines to afford β -lactams) have been got through⁷, one of the most challenging goals currently under active research is the development of methodologies that lead to an effective chiral control in the formation of the corresponding β -lactam. This control can be induced from the two original moieties of the β -lactam ring: chiral esters or chiral imines.^{8,9} The first attempts to prepare optically active β -lactams using ester enolate-imine condensations were reported by Kagan and Luche which obtained, starting from chiral menthyl α -bromo propionate only racemic products^{5b}. Similar results were obtained by Furukawa¹⁰, whereas Bergbreiter and Newcomb were able to obtain β -lactams with up to 60% *ee* starting from lithium enolates of menthyl esters⁶. Better results (91% *ee*) were reported by Hart¹¹ in the synthesis of β -lactam antibiotic PS-5 using as chiral ester enolates that derived from isborneol 10-diisopropylsulfonamide.¹² More recently the identification of chiral 3-hydroxy-4-aryl- β -lactam as precursor of the C-13 side chain of taxol¹³ has promoted research in this area and very high *ee* (98%) have been obtained starting from chiral ester enolates.¹⁴


In the past few years the need of chiral (*R*-)-3-hydroxyethyl azetidinone, to be used as intermediate in the synthesis of penems and carbapenems^{15,16} has been responsible for the explosion of interest in the title reaction. It did not take long for several groups to recognise that the use of enantiopure β -hydroxybutyrate, available in both optical antipodes, as the ester component would lead to β -lactams with α -hydroxyethyl substitution at C(3). Several research groups^{17,18,19,20} including ours²¹, have been involved in the materialisation of this approach (*Chiral nucleophile-achiral electrophile*), since by this way it is possible to synthesise, using as ester the (*3S*)-hydroxy butanoate, the enantiopure 3-hydroxy-ethyl-4-acetoxy-azetidin-2-one. An alternative possibility consists in the use of chiral imines and non-chiral ester enolates (*Achiral nucleophile-chiral electrophile*). This approach results particularly useful to introduce, in the position 3 of the β -lactam ring, an amidic group, crucial for the synthesis of monobactam antibiotics.²² The first attempt to use chiral imines was described by Furukawa, who was able to obtain 18-28% diastereomeric excess (*de*) in reactions between Reformatsky reagents and *N*-(α -methylbenzyl)imines.²³ This approach has been used with greater success by Overman and Osawa.²⁴ In some recent papers from our laboratories²⁵ we have reported the complete diastereoselection observed in the cycloaddition reaction using imines derived from chiral α -silyloxy aldehydes. It is noteworthy that all these methodologies lead to β -lactams which can be elaborated at the C4 position to give useful precursors in the chemical synthesis of β -lactams antibiotics.

In view of the above precedents and within the context of our interest in the study of the synthesis, through *N*-metallo imines, of chiral biological significant nitrogen containing molecules, it is the aim of this work to have a better look inside on the condensation reaction between non-chiral esters and chiral *N*-trimethylsilylimines in which the chiral information is constituted by an imine bearing at the α - or β -position of the imine carbon atom a silyloxy or alkoxy group. Our final goal is to develop methodologies that allow the preparation of β -lactams in high diastereoselectivity.

Results and Discussion.

The formation of the β -lactam ring from an ester enolate and an imine is analogous to the well-known aldol condensation, but includes an additional ring-closure step. The first step of the reaction is activation of the incoming imine by coordination of the imine nitrogen to the metal atom of the enolate.²⁶ This coordination makes the C=N bond more polarized and the carbon becomes a better electrophilic center. Moreover by the evaluation of the ¹³C chemical shift, it has been shown that the presence of a trimethylsilyl group as substituent of the iminic nitrogen, increases the electrophilicity of the iminic carbon itself compared to that of *N*-alkyl or *N*-aryl imines.²⁷ The next step is a nucleophilic attack of the enolate anion on the electrophilic carbon of the imine. During this C-C bond formation, leading to an acyclic amino ester intermediate **A** in equilibrium with the corresponding four membered cyclic structure **B**, two new chiral centres are formed and the stereochemistry of the final product is determined.^{28,29} Elimination of the metal alkoxide finally leads to the end product **C**. (Chart 1)



Chart 1



Simple diastereoselection


The formation of *trans*- and *cis*- β -lactams can be explained by taking into account the transition states as shown in Chart 2. We can assume that under the conditions used, as ample literature suggests, treatment of esters with strong bases affords the *E* enolate^{30,31} and that the imine should exist predominantly as the *E* geometric isomer¹¹. In our studies *N*-trimethylsilylimines have been generated by treatment with LiHMDSA

whereas LDA (Method A) or sodium hexamethyldisilylamide (Method B) were used in the generation of the enolates (Scheme 1). As we will see on the subsequent discussion the two methods give rise to a different facial diastereoselectivity of the reaction³². Moreover we can also assume that under our conditions (-78°C, THF as solvent) the reaction proceeds under kinetic control^{21a}. Keeping fixed the structure of the imine and of the enolate and using the Evans transition state descriptors,²⁹ two possible transition state models, chair like transition state **C(EE)** and boat like transition state **B(EE)** can be invoked to rationalise the stereochemical outcome (from the simple diastereoselection point of view) of the cycloaddition (Chart 2).



The chair-like transition state affords the *cis* azetidinone, the boat-like transition state the *trans* one.³³ In the chair-like transition state **C(EE)** an important 1,3 diaxial non bonded interaction between the enolate alkoxy group and the imine side chain can be observed. In the boat-like transition state **B(EE)** the enolate alkoxy group and the imine side chain are remote from each other. In the case of *N*-trimethylsilylimines the 1,4 apical interaction between the alkoxy group and the trimethylsilyl group appears to be of moderate degree since the two groups are relatively far away because of the *N*-Si bond length of about 1.8 Å. From the two transition-states above reported it appears clear why the simple diastereoselection is largely influenced by the sterical hindrance of the imine side chain: small groups, as linear side chains, give preponderant formation of *cis* azetidinones whereas branched chains give as major isomer *trans* azetidinones. This behaviour is in agreement with the hypothesis that with large imine side chain the non bonded 1,3 interaction in the chair-like transition state becomes too large so that the boat-like transition state corresponds to the lowest energy and leads to the preponderant formation of the *trans* isomer. As a matter of fact, the *N*-trimethylsilylimine of lactal, protected on the hydroxy functionality as alkyl or trialkylsilyl ether, upon addition of enolates affords *exclusively syn-trans* or *anti-trans* azetidinones, aside from the *O*-protecting group (Scheme 2), while *N*-trimethylsilylimines of β -silyloxy aldehydes gives rise to a mixture of *cis* and *trans* isomers depending on the very nature of the substituent in α -position of the iminic carbon atom (Scheme 2, Table 1, 3, 5).

Scheme 2




Concerning the 3-amino derivatives (Table 3), because the *N*-protecting disilyl moiety³⁴ is very susceptible to hydrolysis, the separation by chromatographic techniques was usually accompanied by partial deprotection of the amine function with decomposition of the azetidinone ring. To overcome this problem the crude mixture was hydrolysed in $\text{NH}_4\text{Cl}/\text{HCl}$. After removal of the disilyl moiety, the amine functionality was protected as carbobenzoxy derivative. The NMR of crude azetidinones before and after the protection shown the same diastereomeric ratio (Scheme 3, Table 3).

N-trimethylsilyl imines of β -silyloxy aldehydes, instead, give a mixture of the *cis* and *trans* isomers (Scheme 4, Table 5) the ratio being determined by the substitution on the α -position of the imine side chain. Linear side chains afforded a larger amount of *cis* azetidinone.

For the all azetidinones reported, the relative *cis-trans* stereochemistry has been determined by the coupling constant of the H_3 and H_4 at ^1H NMR, the *J* of the *cis* isomer being always larger than the *trans* one (Tables 2 and 4).³⁵

Scheme 3




Reagents and conditions: *i*: LDA, THF, -78°C ; *ii*: 2; *iii*: HCl 1N (pH 1.5), 2 hrs; *iv*: CbzCl , NaHCO_3 , (pH 8-9), acetone/ H_2O .

With β -silyloxy derivatives, for diagnostic purpose, the diastereomeric ratio has been determined on the crude reaction mixture and the configurations have been assigned by elaboration to the corresponding cyclic acetones (see experimental section). Nevertheless, since in our hands the chromatographic separation of compounds 22 and 23 from 21 resulted a difficult task, the diastereomeric ratio was assigned on the basis of HPLC and ^1H NMR techniques by integration of the characteristic protons C-3 and C-4 on the crude reaction mixture. The structures of 22 and 23 were tentatively assigned on the basis of combinative coupling constants

evaluation (in the case obtained by irradiation) COSY and NOE techniques at 500 MHz instrument. (Scheme 4, Table 5)

Scheme 4



14a, 15a: R¹=R²=H; R³=CH₃; R⁴=TBDMS. 14b, 15b: R¹=CH₃ R²=H; R³=H; R⁴=TBDMS
 14c, 15c: R¹=H; R²=CH₃; R³=H; R⁴=TBDMS

Diastereoface selectivity.

More intriguing appears to be the facial-diastereoselectivity on varying the nature of the *O*-protecting group and the nature of the metal cation used in the formation of *N*-trimethylsilyl imines.

The 1,2-facial diastereoselectivity observed in a given reaction is generally explained by a partitioning of the reaction path *via* a chelated transition state, which exclusively gives the *syn* isomer, and an unchelated one of comparable activation energy that affords a preponderant amount of the *anti* diastereoisomer. This partition has been named by Reetz³⁶ chelation and non chelation control.

Let us take into account the three factors that seem, in the present case, to play a crucial role in determining the 1,2-diastereoselectivity:³⁷

1. The nature of the cations present in the reaction medium.
2. The sterical demanding of the *O*-protecting group of the α -hydroxy functionality.
3. The distance of the silyloxy group from the imine carbon.


1. The nature of the cations present in the reaction medium.

The ester enolates have been generated using as metallating agent lithium diisopropyl amide, lithium or sodium hexamethyldisilyl amide. The use of lithium amides results in a very remarkable *syn-trans* diastereoselectivity whereas using sodium hexamethyldisilylamide the *trans*-diastereoselectivity remains unchanged, as previously discussed, but the *syn* diastereoselectivity decreases. In the case of lithium enolates the observed very high 1,2-*lk* induction of the stereocenter present in the side chain of the imine upon C₄ stereocenter of the azetidinone could be explained *via* a Cram cyclic model by assuming coplanarity between oxygen and nitrogen atoms of the imine due to chelation by lithium cations so that the nucleophile attacks from the less hindered face of the diastereotopic plane. In contrast a lower diastereoselectivity is observed using the sodium enolate as nucleophile (Chart 3).

It is known that the sodium cation is a weaker Lewis acid and cannot efficiently coordinate the two heteroatoms of imine ensuing partition between chelated (highly stereoselective) and unchelated (poorly stereoselective) transition states. Therefore the reaction leads to a significant formation of the *anti* isomer. However the more basic imine nitrogen atom still coordinates the sodium cation so that the simple

diastereoselectivity still proceeds *via* a closed boat-like transition state leading exclusively to the formation of *trans* azetidinone as previously emphasised. The very high *syn* diastereoselectivity invariable shown by the alkoxy derivatives, even in the case of sodium enolates, could be originated by the higher basicity of alkoxy groups in comparison with silyloxy groups so that the chelated model is still operating³⁸.

Chart 3



2. *The sterical demanding of the O-protecting group of the α -hydroxy functionality.* A careful analysis of the results reported in Table 1 and 2 may be interpreted in terms of ability of the *O*-protecting group to form chelated cyclic structure through the coordination as has been recently assumed in an elegant paper by Eliel and Frye. This ability seems strictly correlated to the sterical demanding of the groups directly linked to the silicon³⁹. With the relatively small triethylsilyloxy group the *syn* selectivity is complete, whereas, to an increasing size of the *O*-protecting group corresponds an increasing of *anti* isomer amount. With the big triisopropylsilyloxy group the *syn:anti* ratio becomes 73/27 (Method A) and 17/83 (Method B). (Entries 1, 2 Table 1. See also entries 1, 2 Table 3). Even from this point of view, alkoxy groups show a very high *syn* diastereoselectivity apart from the metal cations used and steric hindrance of the *O*-protecting group itself (See entries 9, 10, 11, 12 Table 1 and entries 9 and 10 Table 3) as a further proof that, with alkoxy groups, the chelated model is still operative.

3. *The distance of the silyloxy group from the iminic carbon: β -Alkoxy imines.*


As we have already seen the control in simple diastereoselectivity for the β -silyloxy imines is less stringent than for the α -silyloxy ones. Examples are known in literature on similar behaviour.³¹ In an oversimplification it has been attributed to a larger freedom degree of the six membered chelated ring compared with the corresponding five-membered cyclic structure.⁴⁰ Because this, different mechanistic pathways and different transition states are involved in determining the stereochemical outcome of the reaction. As result almost all possible stereoisomers are obtained, of course in different ratio depending from substituents and reaction conditions.

In conclusion it must be pointed out that by a careful choice of the enolate cations and of the *O*-protecting groups the configuration of the two contiguous carbon centres on the azetidinone ring can be controlled by the configuration of the stereogenic centre of the starting imine.

Table 1. Asymmetric Synthesis of β -Lactams through Chiral Imines-Alkyl Ester Enolates Condensation.

Entry	R	R ¹	R ²	Method	β -Lactams (<i>Trans</i> 100%)	Isolated Yield (%)	Product ratio <i>Syn/Anti</i>	Ref
1	CH ₃	TIPS	C ₂ H ₅	A	5a/6a	60	73/27	
2	CH ₃	TIPS	C ₂ H ₅	B	5a/6a	51	17/83	
3	CH ₃	TBDPS	C ₂ H ₅	A	5b/6b	53	90/10	
4	CH ₃	TBDPS	C ₂ H ₅	B	5b/6b	31	7/93	
5	CH ₃	TBDMS	C ₂ H ₅	A	5c/6c	63	96/4	25g, j
6	CH ₃	TBDMS	C ₂ H ₅	B	5c/6c	38	70/30	25i
7	CH ₃	TES	C ₂ H ₅	A	5d/6d	40	>98/<2	
8	CH ₃	TES	C ₂ H ₅	B	5d/6d	35	90/10	
9	CH ₃	<i>tert</i> -Bu	C ₂ H ₅	A	5e/6e	25	>98/<2	
10	CH ₃	<i>tert</i> -Bu	C ₂ H ₅	B	5e/6e	20	>98/<2	
11	CH ₃	Bn	C ₂ H ₅	A	5f/6f	42	>98/<2	
12	CH ₃	Bn	C ₂ H ₅	B	5f/6f	10	>98/<2	
13	C ₂ H ₅	TBDMS	C ₂ H ₅	A	5g/6g	41	93/7	
14	CH ₃	TBDMS	<i>i</i> -Pr	A	5h/6h	61	>98/<2	25g
15	CH ₃	TBDMS	<i>tert</i> -Bu	A	5i/6i	68	>98/<2	
16	Ph	TBDMS	C ₂ H ₅	A	5j/6j	84	>98/<2	
17	Ph	TBDMS	<i>i</i> -Pr	A	5m/6m	70	>98/<2	

TIPS=Triisopropylsilyl; TBDPS: *tert*-Butyldiphenylsilyl; TBDMS: *tert*-Butyldimethylsilyl; TES: Triethylsilyl.


Table 2 ¹H and ¹³C NMR data for Azetidinones 5, 6.

Comp.	H-3	H-4	H-5	C-2	C-3	C-4	C-5
5a	2.70 m	3.20 (dd, J=2.35; 7.52)	3.90 (dq, J=6.22; 7.52)	170.91	54.40	60.25	71.21
6a	3.00 m	3.25 (dd, J=2.23; 3.84)	4.05 (dq, J=3.84; 6.22)	171.83	53.60	59.78	68.61
5b	2.65 m	3.30 (dd, J=2.26; 7.33)	3.80 (dq, J=6.25; 7.33)	170.62	50.34	60.00	72.09
6b	2.95 m	3.15 (dd, J=2.10; 3.92)	3.95 (dq, J=3.90; 6.24)	171.22	53.50	59.34	68.81
5c	2.71 (dt, J=2.57; 7.03)	3.18 (dd, J=2.57; 8.86)	3.75 (quintet, J=8.86)	168.80	52.40	57.80	68.90
6c	2.85 (dt, J=2.52; 7.21)	3.15 (dd, J=2.53; 5.64)	3.85 m	171.55	53.80	56.60	68.60
5d	2.68 m	3.15 (dd, J=2.23; 7.81)	3.73 (quintet, J=6.35)	170.58	54.60	59.93	71.20
6d	2.94 m	3.19 (dd, J=2.10; 4.65)	3.87 (quintet, J=6.52)	171.44	54.18	59.61	68.60
5e	2.70 m	3.20 (dd, J=2.25; 8.04)	3.60 (dq, J=6.2; 8.04)	170.73	54.71	58.65	70.13
5f	2.70 m	3.20 (dd, J=2.28; 8.04)	3.45 (dq, J=6.1; 8.04)	170.72	55.05	58.32	70.86
5g	2.75 m	3.30 (dd, J=2.33; 7.52)	3.55 (m, J(4-5)=7.52)	170.55	54.62	57.84	75.83
6g	3.00 m	3.30 (dd, J=2.10; 3.92)	3.70 (m, J(4-5)=3.92)	171.52	53.64	57.51	73.19
5h	2.58 (dt, J=2.24; 7.65)	3.22 (dd, J=2.24; 7.65)	3.75 (quintet, J=7.65)	170.31	58.10	59.90	71.30
5i	2.50 (t, J=1.75)	3.14 (dd, J=2.10; 6.20)	3.65 (quintet, J=6.31)	169.71	56.51	63.41	70.92
5j	2.70 m	3.33 (dd, J=2.26; 7.53)	4.50 (d, J=7.53)	170.63	54.19	60.40	77.87
5m	2.62 (ddd, J=2.23; 2.04; 7.85)	3.41 (dd, J=2.22; 7.51)	4.50 (d, J=7.501)	170.05	58.60	59.60	78.36

Table 3. Asymmetric Synthesis of β -Lactams through Chiral Imines-STABASE Enolate Condensation.

Entry	R	R ¹	Method	β -Lactams (<i>Trans</i> 100%)	Yield (%) [*]	<i>Syn/Anti</i> ratio	Ref
1	CH ₃	TIPS	A	12a/13a	56	90/10	25b
2	CH ₃	TIPS	B	12a/13a	65	15/85	25b
3	CH ₃	TBDPS	A	12b/13b	20	>98/<2	
4	CH ₃	TBDPS	B	12b/13b	36	9/91	
5	CH ₃	TBDMS	A	12c/13c	85	>98/<2	25h
6	CH ₃	TBDMS	B	12c/13c	73	40/60	25h
7	CH ₃	TES	A	12d/13d	54	>98/<2	
8	CH ₃	TES	B	12d/13d	40	96/4	
9	CH ₃	<i>tert</i> -Bu	A	12e/13e	39	>98/<2	
10	CH ₃	<i>tert</i> -Bu	B	12e/13e	55	>98/<2	
11	Ph	TBDMS	A	12f/13f	40	>98/<2	25h

^{*}Determined on the isolated Cbz derivatives. TIPS=Triisopropylsilyl; TBDPS: *tert*-Butyldiphenylsilyl; TBDMS: *tert*-Butyldimethylsilyl; TES: Triethylsilyl.

Table 4 ¹H and ¹³C NMR data for Azetidiones 12, 13.

Comp.	H-3	H-4	H-5	C-2	C-3	C-4	C-5
12a	4.50 (dd, J=2.10; 8.35)	3.50 (dd, J=2.10; 6.52)	4.00 (quintet, J=6.03)	168.58	60.32	63.59	66.99
13a	4.75 (dd, J=2.10; 8.62)	3.60 m	4.15 m	167.73	58.73	62.47	66.69
12b	4.35 (dd, J=2.02; 8.30)	3.60 (dd, J=2.04; 6.92)	3.85 (quintet, J=6.90)	167.12	66.99	63.14	60.33
13b	4.75 (dd, J=1.00; 8.63)	3.50 m	3.95 m	167.10	67.22	62.16	59.05
12c	4.60 (d, J=7.65)	3.65 m	4.80 m	167.80	59.90	63.25	74.15
13c	4.75 (dd, J=2.10; 8.65)	3.60 m	4.15 m	167.73	58.73	62.47	67.06
12d	4.5 (dd, J=2.02; 9.01)	3.45 (dd, J=2.02; 7.45)	3.85 (quintet, J=6.93)	167.48	67.13	63.61	60.60
13d	4.70 (dd, J=2.03; 8.64)	3.55 m	3.93 m	167.40	65.50	62.59	60.40
12e	4.63 (dd, J=1.83, 9.45)	3.55 m	3.55 m	169.41	60.58	63.15	66.73

Table 5. Asymmetric Synthesis of β -Lactams through β -silyloxy Chiral Imines-Ester Enolates Condensation.

Entry	Imine	Meth	β -Lactams	R ¹	R ²	R ³	Isolated Yield (%)	Product ratio (<i>cis/trans</i>) [*]	Ref.
1	15a	A	16a:17a:18a:19a	H	H	CH ₃	46	75:8:15:2(83/17)	
2	15b	A	16b:17b:18b:19b	CH ₃	H	H	52	15/2/75/8 (17/83)	25f
3	15c	A	16c:17c:18c:19c	H	CH ₃	H	59	15/0/72/13(15/85)	41

^{*}The products ratio showed to be the same for the open-chains and acetonide derivatives by HPLC analyses

Experimental Section

General: Melting points are uncorrected. All reactions were conducted under nitrogen atmosphere. THF was distilled from Na/benzophenone ketyl and CH₂Cl₂ was distilled from P₂O₅. ¹H-NMR spectra were recorded at 200 and 500 MHz in CDCl₃ using residual of CHCl₃ as internal references. All reactions were performed under argon atmosphere.

General Procedure for the Synthesis of α -Silyloxy aldehydes.

To a solution of hydroxy ester (30 mmol) and imidazole (60 mmol) in anhydrous DMF (30 ml) cooled with ice-water were added 30 mmol of the appropriate silyl-chloride. After ten minutes the bath was removed and the reaction was left at room temperature for three hours. The mixture was poured in ice-water and extracted with hexane (3x50ml) which was washed with brine (2x50ml), dried (Na₂SO₄) and concentrated in vacuo. To a solution of the appropriate ester (20 mmol) in anhydrous ether (80 ml) was added dropwise diisobutylaluminiumhydride (DIBAH) in hexane (30 mmol, 30 ml, 1 M) by a side arm at -78 °C. After being stirred at the same temperature for the time to consume the starting ester (from 15 min to 2 hr) the mixture was poured in ice water and extracted with ether. The solvent was washed twice with diluted cold hydrochloric acid, brine, dried and concentrated in vacuo. The residue was chromatographed on silica gel (hexane-ethyl acetate 9:1) to give the target aldehyde.

Ethyl (S)-2-[(Triisopropylsilyl)oxy]-2-propanoate

$[\alpha]_D^{20} = -16.5$ (c 1.95, CHCl₃); IR (CHCl₃) 1750 cm⁻¹; ¹H NMR 1.05 (m, 21H), 1.25 (t, 3H, J=7.1), 1.40 (d, 3H, J=6.70), 4.15 (q, 2H, J=6.70), 4.45 (q, 1H, J=7.1); ¹³C NMR 174.18, 68.47, 60.59, 21.72, 17.79, 14.14, 12.08.

(S)-2-[(Triisopropylsilyl)oxy]-2-propanal

$[\alpha]_D^{20} = -8.4$ (c 2.72, CHCl₃); IR (CHCl₃) 1736 cm⁻¹; ¹H NMR 1.08 (m, 21H), 1.30 (d, 3H, J=6.8), 4.20 (dq, 1H, J=1.58, 6.8), 9.65 (d, 1H, J=1.58); ¹³C NMR 204.06, 73.72, 18.78, 17.76, 12.05.

Ethyl (S)-2-(*tert*-Butyloxy)-2-propanoate

$[\alpha]_D^{20} = -41.0$ (c 2.04, CHCl₃); IR (CHCl₃) 1745 cm⁻¹; ¹H NMR 1.10 (s, 9H), 1.20 (t, 3H, J=7.1), 1.25 (d, 3H, J=6.8), 4.07 (m, 3H); ¹³C NMR 174.88, 74.62, 67.35, 60.40, 27.56, 20.32, 13.97.

(S)-2-(*tert*-Butyloxy)-2-propanal

$[\alpha]_D^{20} = -77.0$ (c 2.05, CHCl₃); IR (CHCl₃) 1738 cm⁻¹; ¹H NMR 1.16(d, 3H, J=6.9), 1.17 (s, 9H), 3.87 (dq, 1H, J=2.1, 6.9), 9.55 (d, 1H, J=2.1); ¹³C NMR 205.40, 74.78, 72.85, 28.14, 17.45.

Ethyl (S)-2-[(Triethylsilyl)oxy]-2-propanoate

$[\alpha]_D^{20} = -28.6$ (c 1.94, CHCl₃); IR (CHCl₃) 1750 cm⁻¹; ¹H NMR 0.60(q, 6H, J=8.10), 0.95 (t, 9H, J=8.10), 1.23 (t, 3H, J=7.1), 1.40 (d, 3H, J=6.72), 4.13 (q, 2H, J=7.1), 4.30 (q, 1H, J=6.7); ¹³C NMR 173.93, 68.07, 60.60, 21.23, 14.07, 6.52, 4.56.

(S)-2-[(Triethylsilyl)oxy]-2-propanal

$[\alpha]_D^{20} = -11.5$ (c 1.55, CHCl₃); IR (CHCl₃) 1735 cm⁻¹; ¹H NMR 0.60(q, 6H, J=7.85), 0.95 (t, 9H, J=7.85), 1.25 (d, 3H, J=6.84), 4.05 (dq, 1H, J=1.34, 6.84), 9.60 (d, 1H, J=1.34); ¹³C NMR 204.12, 73.46, 18.53, 6.59, 4.68.

General Procedure for the Synthesis of *N*-Trimethylsilyl imines.

To a 1 M solution of LiHMDSA in THF (10 ml), under argon atm, 10 mmol of the aldehyde in 30 ml of THF at -40°C were added. The mixture was stirred at the same temperature for 40 min, and the resulting cold solution of *N*-trimethylsilylimine was used directly for the condensation with the ester enolate (see below).

General Procedure for the preparation of Azetidinones (5a-5m and 6a-6m)

Method A : To a solution of diisopropylamine (1.01 g, 10 mmol) in anhydrous THF (20 ml) was added *n*-butyllithium in hexane (4 ml 2.5 N sol., 10 mmol) at -78°C. The solution was stirred for 10 min followed by addition of ester (10 mmol) in THF (5 ml) at a rate such that the temperature did not exceed -60°C. The solution was stirred for 1 h followed by addition of the *N*-trimethylsilylimine (1eq), prepared as previously reported, *via* cannula over a 5 min period. The mixture was stirred at -78°C for 15 min., the cold bath was

removed, and the mixture was allowed to warm to room temperature followed by stirring overnight. The solution was diluted with 100 ml of ethyl acetate and washed sequentially with 50 mL of a saturated solution of NH_4Cl and 50 ml of water. The combined aqueous washes were extracted with 100 ml portions of ethyl acetate. The organic layers were dried and concentrated *in vacuo*. Diastereomeric ratio were determined on the crude reaction mixture by a combined HPLC, ^1H and ^{13}C NMR spectra. The residue was purified (hexane/ethyl acetate) to give the β -lactams reported in Table 1 in yields and ratio therein indicated.

Method B : Same protocol of *Method A* but NaHMDSA was used for the preparation of ester enolates.

(3R, 4S)-3-Ethyl-4-[(S)-1-(triisopropylsilyloxy)-ethyl]-2-azetidinone. 5a

IR (CHCl₃) 1775 cm⁻¹. ^1H NMR 1.05 (m, 21H), 1.20 (d, 3H, J=6.2), 1.75 (m, 2H), 2.70 (m, 1H), 3.20 (dd, 1H, J=2.35, 7.52), 3.90 (dq, 1H, J=6.22, 7.52), 6.00 (s, 1H); ^{13}C NMR 170.91, 71.22, 60.25, 54.40, 21.37, 20.03, 18.04, 12.51, 11.49. Anal. Calcd for C₁₆H₃₃NO₂Si: C, 64.16; H, 11.10; N, 4.68. Found: C, 64.35; H, 11.15; N, 4.70.

(3S, 4R)-3-Ethyl-4-[(S)-1-(triisopropylsilyloxy)-ethyl]-2-azetidinone. 6a

IR (CHCl₃) 1775 cm⁻¹. ^1H NMR 1.05 (m, 21H), 1.20 (d, 3H, J=6.2), 1.75 (m, 2H), 3.00 (m, 1H), 3.25 (dd, 1H, J=2.23, 3.84), 4.05 (dq, 1H, J=3.84, 6.22), 6.00 (s, 1H); ^{13}C NMR 171.83, 68.61, 59.78, 53.60, 21.56, 20.14, 18.06, 12.51, 11.58. Anal. Calcd for C₁₆H₃₃NO₂Si: C, 64.16; H, 11.10, N, 4.68. Found: C, 63.98; H, 11.20; N, 4.60.

(3R, 4S)-3-Ethyl-4-[(S)-1-(tert-butylidiphenylsilyloxy)-ethyl]-2-azetidinone. 5b

IR (CHCl₃) 1765 cm⁻¹; ^1H NMR 1.00 (t, 3H, J=7.3), 1.10 (m, 12H), 1.70 (m, 2H), 2.65 (m, 1H), 3.30 (dd, 1H, J=2.26, 7.33), 3.80 (dq, 1H, J=6.25, 7.33), 6.10 (s, 1H), 7.3-7.7 (m, 10H); ^{13}C NMR 170.62, 135.89, 135.79, 135.62, 133.75, 133.60, 129.98, 129.91, 127.92, 127.74, 72.09, 60.00, 54.35, 27.00, 21.36, 19.84, 19.26, 11.53. *m/z* 323 (M⁺-57); 280; 253. Anal. Calcd for C₂₃H₃₁NO₂Si: C, 72.40; H, 8.19; N, 3.67. Found: C, 72.60; H, 8.21; N, 3.58.

(3S, 4R)-3-Ethyl-4-[(S)-1-(tert-butylidiphenylsilyloxy)-ethyl]-2-azetidinone. 6b

IR (CHCl₃) 1765 cm⁻¹; ^1H NMR 1.00 (t, 3H, J=7.3), 1.10 (m, 12H), 1.70 (m, 2H), 2.95 (m, 1H), 3.15 (dd, 1H, J=2.10, 3.92), 3.95 (dq, 1H, J=3.90, 6.24), 6.15 (s, 1H), 7.3-7.7 (m, 10H); ^{13}C NMR 171.22, 135.93, 135.89, 134.10, 133.43, 129.95, 129.86, 127.92, 127.80, 127.72, 68.81, 59.34, 53.50, 27.00, 21.53, 19.77, 19.22, 11.56. *m/z* 323 (M⁺-57); 280; 253. Anal. Calcd for C₂₃H₃₁NO₂Si: C, 72.40; H, 8.19; N, 3.67. Found: C, 72.55; H, 8.20; N, 3.55.

(3R, 4S)-3-Ethyl-4-[(S)-1-(triethylsilyloxy)-ethyl]-2-azetidinone. 5d

IR (CHCl₃) 1765 cm⁻¹; ^1H NMR 0.58 (q, 6H); 0.92 (t, 9H); 0.95 (t, 3H); 1.13 (d, 3H, J=6.25); 1.72 (m, 2H); 2.68 (m, 1H); 3.15 (dd, 1H, J=2.23, 7.81); 3.73 (quintet, 1H, J=6.35); 6.0 (bs, 1H). ^{13}C NMR 170.58, 71.20, 59.93, 54.60; 21.32; 20.04; 11.47; 6.76, 4.90. Anal. Calcd for C₁₃H₂₇NO₂Si: C, 60.65; H, 10.57; N, 5.44. Found: C, 60.80; H, 10.60; N, 5.43.

(3S, 4R)-3-Ethyl-4-[(S)-1-(triethylsilyloxy)-ethyl]-2-azetidinone. 6d

IR (CHCl₃) 1770 cm⁻¹; ^1H NMR 0.60 (q, 6H); 0.95 (t, 9H); 1.02 (t, 3H); 1.14 (d, 3H, J=6.2); 1.70 (m, 2H); 2.94 (m, 1H); 3.19 (dd, 1H, J=2.10, 4.65); 3.87 (quintet, 1H, J=6.52); 5.90 (bs, 1H). ^{13}C NMR 171.44, 68.60, 59.61, 54.18; 21.59; 20.23; 11.65, 6.77, 4.86. Anal. Calcd for C₁₃H₂₇NO₂Si: C, 60.65; H, 10.57; N, 5.44. Found: C, 60.85; H, 10.55; N, 5.45.

(3S, 4R)-3-Ethyl-4-[(S)-1-(tert-butoxy)-ethyl]-2-azetidinone. 5e

IR (CHCl₃) 1755 cm⁻¹; ^1H NMR 1.05 (t, 3H, J=7.4), 1.15 (d, 3H, J=6.2), 1.20 (s, 9H), 1.75 (m, 2H), 2.70 (m, 1H), 3.20 (dd, 1H, J=2.25, 8.04), 3.60 (dq, 1H, J=6.20, 8.04), 6.55 (s, 1H); *m/z* 199 (M⁺); 183; 170; 153. ^{13}C NMR 170.73, 73.72, 70.13, 58.65, 54.71, 28.59, 21.32, 19.27, 11.33. Anal. Calcd for C₁₁H₂₁NO₂: C, 66.29; H, 10.62, N, 7.03. Found: C, 66.39; H, 10.67; N, 7.00.

(3R, 4S)-3-Ethyl-4-[(S)-1-(benzyloxy)-ethyl]-2-azetidinone. 5f

IR (CHCl₃) 1780 cm⁻¹; ^1H NMR 1.00 (t, 3H), 1.15 (d, 3H, J=7.3), 1.70 (m, 2H), 2.70 (m, 1H), 3.20 (dd, 1H, J=2.28, 8.04), 3.45 (dq, 1H, J=6.10, 8.04), 4.50 (m, 2H), 6.60 (s, 1H), 7.30 (m, 5H). ^{13}C NMR 170.72, 138.27, 128.43, 127.70, 77.47, 70.86, 58.32, 55.05, 21.39, 15.75, 11.49. Anal. Calcd for C₁₄H₁₉NO₂: C, 72.07; H, 8.21, N, 6.00. Found: C, 72.25; H, 8.25; N, 5.80.

(3R, 4S)-3-Ethyl-4-[(S)-1-(tert-Butyldimethylsilyloxy)-propyl]-2-azetidinone. 5g

IR (CHCl₃) 1780, 1765 cm⁻¹; ¹H NMR 0.05 (s, 3H), 0.07 (s, 3H), 0.88 (s, 9H), 0.93 (t, 3H, J=7.3), 1.02 (t, 3H, J=7.4), 1.50 (m, 2H), 1.75 (m, 2H), 2.75 (m, 1H), 3.30 (dd, 1H, J=2.33, 7.52), 3.55 (m, 1H, J_{4,5}=7.52), 5.80 (s, 1H); ¹³C NMR 170.55, 75.83, 57.84, 54.62, 26.80, 25.80, 21.32, 18.07, 11.28, 9.07, -4.25, -4.32. *m/z* 199 (M⁺-72); 144. Anal. Calcd for C₁₄H₂₉NO₂Si: C, 61.94; H, 10.77, N, 5.16. Found: C, 61.74; H, 10.73; N, 5.18.

(3S, 4R)-3-Ethyl-4-[(S)-1-(*tert*-Butyldimethylsilyloxy)-propyl]-2-azetidinone. 6g

IR (CHCl₃) 1785, 1760 cm⁻¹; ¹H NMR 0.05 (s, 3H), 0.07 (s, 3H), 0.88 (s, 9H), 0.92 (t, 3H, J=7.3), 1.00 (t, 3H, J=7.4), 1.48 (m, 2H), 1.73 (m, 2H), 3.00 (m, 1H), 3.30 (dd, 1H, J=2.1, 3.9), 3.70 (m, 1H, J_{4,5}=3.92), 6.00 (s, 1H); ¹³C NMR 171.52, 73.19, 57.51, 53.64, 27.37, 25.81, 21.55, 18.05, 11.51, 9.43, -4.43, -4.47. Anal. Calcd for C₁₄H₂₉NO₂Si: C, 61.94; H, 10.77, N, 5.16. Found: C, 61.84; H, 10.63; N, 5.20.

(3R, 4S)-3-*tert*-Butyl-4-[(S)-1-(*tert*-butyldimethylsilyloxy)-ethyl]-2-azetidinone. 5i

IR (CHCl₃) 1760 cm⁻¹; ¹H NMR -0.06 (s, 6H), 0.88 (s, 9H), 0.92 (s, 9H), 1.07 (d, 3H, J=6.0), 2.50 (t, 1H, J=1.7), 3.14 (dd, 1H, J=2.10, 6.20), 3.65 (quintet, 1H, J=6.31), 6.35 (s, 1H); ¹³C NMR 169.71, 70.92, 63.41, 56.51, 30.34, 27.38, 25.62, 20.17, 17.77, -4.48, -4.89. Anal. Calcd for C₁₅H₃₁NO₂Si: C, 63.10; H, 10.94, N, 4.91. Found: C, 63.24; H, 10.98; N, 4.88.

General procedure for the preparation of azetidinones. (12a-12e)

To a 1 M solution of LiHMDSA (*syn*-adduct procedure, Method A) or NaHMDS (*anti*-adduct procedure, Method B) in THF (33.7 ml) were added, a -78°C, 8.3 g (33.7 mmol) of STABASE 2 in 10 ml of THF. The mixture was stirred for 2 h followed by addition of *N*-(trimethylsilyl)imine 2 (1 eq) via cannula over a 10 min period. The mixture was allowed to warm, spontaneously, to room temperature and stirred overnight. To this brown solution, at 0°C, 50 ml of NH₄Cl_{aq} were added and the pH was adjusted to 4 by addition of 1 N solution of HCl, followed by addition of 5.0 g of NaHCO₃ (pH 8). Benzylchloroformate (6.8 g, 40 mmol), dissolved in 20 ml of acetone, was added dropwise. After stirring at room temperature (3 hrs), the reaction mixture was extracted with ethyl acetate (500 ml) and the organic layers were washed with brine, dried and concentrated in vacuo. The residue was purified by flash chromatography (hexane-ethyl acetate 1:1)

(3R,4S)-3-(Benzyloxycarbonylamino)-4-[(S)-1-(*tert*-butyldiphenylsilyloxy)-ethyl]-2-azetidinone 12b

IR (CHCl₃) 1764, 1720 cm⁻¹; ¹H NMR 1.05 (s, 9H), 1.15 (d, 3H, J=6.3), 3.60 (dd, 1H, J=2.04, 6.92), 3.85 (quintet, 1H, J=6.90), 4.35 (dd, 1H, J=2.02, 8.30), 5.10 (s, 2H), 5.65 (d, 1H, J=8.3), 6.05 (s, 1H), 7.3-7.8 (m, 15H); ¹³C NMR 167.12, 155.40, 135.67, 135.48, 133.46, 133.41, 129.85, 129.75, 128.33, 128.14, 128.01, 127.94, 127.78, 127.57, 70.88, 66.99, 63.14, 60.33, 26.79, 19.59, 19.06. Anal. Calcd for C₂₉H₃₄N₂O₄Si: C, 69.29; H, 6.82, N, 5.57. Found: C, 69.60; H, 6.85; N, 5.52.

(3S,4R)-3-(Benzyloxycarbonylamino)-4-[(S)-1-(*tert*-butyldiphenylsilyloxy)-ethyl]-2-azetidinone 13b

IR (CHCl₃) 1765, 1720 cm⁻¹; ¹H NMR 1.05 (s, 9H), 1.15 (d, 3H, J=6.3), 3.50 (m, 1H), 3.95 (m, 1H), 4.75 (dd, 1H, J=1.00, 8.63), 5.10 (s, 2H), 5.60 (d, 1H, J=8.6), 5.70 (s, 1H), 7.2-7.8 (m, 15H); ¹³C NMR 167.10, 155.39, 135.89, 133.84, 133.38, 129.98, 129.82, 128.51, 128.18, 128.08, 127.83, 127.74, 127.62, 67.22, 62.16, 59.05, 26.97, 19.74, 19.19. Anal. Calcd for C₂₉H₃₄N₂O₄Si: C, 69.29; H, 6.82, N, 5.57. Found: C, 69.60; H, 6.85; N, 5.55.

(3R,4S)-3-(Benzyloxycarbonylamino)-4-[(S)-1-(triethylsilyloxy)-ethyl]-2-azetidinone 12d

IR (CHCl₃) 1760, 1720 cm⁻¹; ¹H NMR 0.65 (q, 6H), 1.00 (t, 9H), 1.25 (d, 3H, J=6.1), 3.45 (dd, 1H, J=2.02, 7.45), 3.85 (quintet, 1H, J=6.93), 4.55 (dd, 1H, J=2.02, 9.01), 5.10 (s, 2H), 6.20 (d, 1H, J=9.0), 7.00 (s, 1H), 7.35 (s, 5H); ¹³C NMR 167.48, 155.62, 128.47, 128.27, 128.14, 128.03, 69.79, 67.13, 63.61, 60.60, 20.10, 6.72, 4.97. Anal. Calcd for C₁₉H₃₀N₂O₄Si: C, 60.29, H, 7.99, N, 7.40. Found: C, 60.35; H, 8.03, N, 7.35.

(3S,4R)-3-(Benzyloxycarbonylamino)-4-[(S)-1-(triethylsilyloxy)-ethyl]-2-azetidinone 13d

IR (CHCl₃) 1765, 1725 cm⁻¹; ¹H NMR 0.60 (q, 6H), 0.90 (t, 9H), 1.20 (d, 3H, J=6.10), 3.55 (m, 1H), 3.93 (m, 1H), 4.70 (dd, 1H, J=2.03, 8.64), 5.10 (s, 2H), 6.05 (d, 1H, J=8.60), 6.70 (s, 1H), 7.35 (s, 5H). Anal. Calcd for C₁₉H₃₀N₂O₄Si: C, 60.29, H, 7.99, N, 7.40. Found: C, 60.32; H, 7.96, N, 7.43.

(3R,4S)-3-(Benzyloxycarbonylamino)-4-[(S)-1-*tert*-butoxy-ethyl]-2-azetidinone 12e

¹H NMR 1.14 (s, 9H), 1.19 (d, 3H, J=5.90), 3.55 (m, 2H), 4.63 (dd, 1H, J=1.83, 9.45), 5.05 (AB, 2H), 6.70 (d, 1H, J=9.45), 7.30 (s, 5H), 8.00 (s, 1H). ¹³C NMR 169.41, 155.76, 136.24, 128.34, 127.88, 127.71, 73.96, 69.40, 66.73, 63.15, 60.58, 28.58, 19.37. Anal. Calcd for C₁₇H₂₄N₂O₄: C, 63.73, H, 7.55, N, 8.74. Found: C, 63.92; H, 7.58, N, 8.72.

(±)-(3R, 4R)-4-[(R)-2-(*tert*-Butyldimethylsilyloxy)propyl]-3-Ethyl-Azetidin-2-one 16a

IR (CHCl₃) 1765 cm⁻¹; ¹H NMR 0.04 (s, 3 H), 0.06 (s, 3 H), 0.90 (s, 9 H), 1.05 (t, 3 H, J=5.60), 1.18 (d, 3 H, J=6.22), 1.65 (m, 4 H), 3.12 (m, 1 H), 3.68 (m, 1 H), 3.90 (m, 1 H), 6.10 (bs, 1H). ¹³C NMR 171.51, 68.61, 54.97, 50.43, 40.40, 25.89, 24.48, 18.32, 17.96, 12.59, -4.38, -4.52. MS *m/z* 271 (M⁺). Anal. Calcd for C₁₄H₂₉NO₂Si: C, 61.90, H, 10.77, N, 5.16. Found: C, 61.81; H, 10.70, N, 5.10.

(±)-(3*R*, 4*S*)-4-[(*R*)-2-(*tert*-Butyldimethylsilyloxy)propyl]-3-Ethyl-Azetidin-2-one 17a

IR (CHCl₃) 1775 cm⁻¹; ¹H NMR 0.04 (s, 3 H), 0.06 (s, 3 H), 0.90 (s, 9 H), 1.05 (t, 3 H, J=5.64), 1.18 (d, 3 H, J=6.22), 1.65 (m, 4 H), 3.12 (m, 1 H), 3.93 (m, 2 H), 5.90 (bs, 1H). ¹³C NMR 171.88, 66.48, 54.77, 48.42, 39.69, 25.87, 23.86, 18.34, 18.02, 12.60, -4.32, -4.80. Anal. Calcd for C₁₄H₂₉NO₂Si: C, 61.94, H, 10.77, N, 5.16. Found: C, 61.88.92; H, 10.73, N, 5.18.

(±)-(3*S*, 4*R*)-4-[(*R*)-2-(*tert*-Butyldimethylsilyloxy)propyl]-3-Ethyl-Azetidin-2-one 18a

IR (CHCl₃) 1765 cm⁻¹; ¹H NMR 0.02 (s, 3 H), 0.01 (s, 3 H), 0.85 (s, 9 H), 0.98 (t, 3 H, J=5.72), 1.12 (d, 3 H, J=6.35), 1.68 (m, 4 H), 2.65 (m, 1 H), 3.43 (ddd, 1 H, J=2.32, 4.05, 9.22), 3.86 (m, 1 H), 6.25 (bs, 1H).

(±)-(3*S*, 4*S*)-4-[(*R*)-2-(*tert*-Butyldimethylsilyloxy)propyl]-3-Ethyl-Azetidin-2-one 19a

IR (CHCl₃) 1765 cm⁻¹; ¹H NMR 0.02 (s, 3 H), 0.01 (s, 3 H), 0.85 (s, 9 H), 0.98 (t, 3 H, J=5.70), 1.13 (d, 3 H, J=6.32), 1.68 (m, 4 H), 2.65 (m, 1 H), 3.33 (ddd, 1 H, J=2.10, 5.82, 6.63), 3.86 (m, 1 H), 6.2 (bs, 1H).

General procedure for the preparations of acetonides (20, 21, 22 and 23)

A solution of azetidinone **16a** (*e.g.*) (1.6 g, 5.9 mmol) in 3 ml of acetonitrile containing 5% of 40% aqueous HF, was stirred at room temperature for 30 min. The mixture was evaporated and flash chromatographed on SiO₂ (eluting with ethyl acetate) to give the alcohol **16a** in quantitative yield. A solution of **16a** (10 mmol) in anhydrous CH₂Cl₂ (15 ml), 2,2-dimethoxypropane (10 mmol) and a catalytic amount of (Et)₂O BF₃ (0.1 ml) was stirred at room temperature for 3 h. The mixture was diluted with ethyl acetate (50 ml), washed with brine, dried (Na₂SO₄), evaporated and the residue was purified on SiO₂ (eluting hexane/ethyl acetate 70/30) to give **20a**.

(±)-(4*R*, 6*R*, 7*R*)-7-Ethyl-2,2,4-trimethyl-3-Oxa-Bicyclo [4.2.0.] Octan-8-One 20a

IR (CHCl₃) 1745 cm⁻¹. ¹H NMR (CDCl₃) 1.04 (t, 3H, J=7.00), 1.21 (d, 3H, J=6.52), 1.39 (s, 3 H), 1.50-1.60 (m, 1 H); 1.68 (s, 3 H), 1.64-1.72 (m, 1 H), 1.73-1.90 (m, 1 H), 1.87 (dt, 1 H, J=3.83, 13.8), 3.04 (ddd, 1 H, J=5.23, 7.61, 9.04), 3.74-3.80 (m, 2 H).

(±)-(4*R*, 6*S*, 7*R*)-7-Ethyl-2,2,4-trimethyl-3-Oxa-Bicyclo [4.2.0.] Octan-8-One 21a

IR (CHCl₃) 1743 cm⁻¹. ¹H NMR (CDCl₃) 0.99 (t, 3 H, J=7.00), 1.22 (d, 3 H, J=6.52), 1.39 (s, 3 H), 1.36 (m, 1H), 1.70-1.82 (m, 1 H), 1.75 (s, 3 H), 3.10 (ddd, 1H, J= 5.37, 6.84, 9.77), 3.69 (dt, 1 H, J=4.82, 12.25), 3.91 (m, 1 H). ¹³C NMR (C₆D₆) 169.27, 85.64, 64.47, 53.39, 45.52, 32.08, 28.52, 24.13, 21.43, 19.14, 12.62; MS *m/z* 182 (M⁺-15).

(±)-(4*R*, 6*R*, 7*S*)-7-Ethyl-2,2,4-trimethyl-3-Oxa-Bicyclo [4.2.0.] Octan-8-One 22a

¹H NMR (CDCl₃) 3.36 (ddd, 1 H, J=1.43, 4.45, 10.98), 3.88 (m, 1 H)

(±)-(4*R*, 6*S*, 7*S*)-7-Ethyl-2,2,4-trimethyl-3-Oxa-Bicyclo [4.2.0.] Octan-8-One 23a

¹H NMR (CDCl₃) 3.25 (ddd, 1 H, J=1.43, 4.45, 10.98), 3.78 (dt, 1 H, J=1.45, 12.40)

Acknowledgement. Financial support was provided by "Progetto Strategico Tecnologie Chimiche Innovative and Progetto Finalizzato Chimica Fine II" CNR-Rome. Thanks are due to Miss Michaela Fabbri for HPLC measurements and to Dr. Carla Marchioro (Analytical Sciences Department - Glaxo S.p.A.- Verona) for ¹H NMR 500 MHz spectra.

References and Notes

- Gilman, H.; Speeter, M. *J. Am. Chem. Soc.* **1943**, *65*, 2255.
- (a) Hart, D.J.; Ha, D.C. *Chem. Rev.* **1989**, *89*, 1447. (b) van Koten, G.; van der Steen, F.H.. *Tetrahedron* **1991**, *47*, 7503. (c) Georg, I. G. "Studies in Natural Products Chemistry" ed. Rahman, A., Ed.; Elsevier Science: Amsterdam 1989, Vol. 4, p. 4331. (c) Brown, M.J. *Heterocycles* **1989**, *29*, 2225.
- Chemistry and Biology of β-Lactam Antibiotics*; Morin R.B., Gorman, M.; Eds.; Academic Press: New York, 1982; Vol. 1-3

- 4 (a) Manhas, M.S.; Amiun, S.G.; Bose, A.K. *Heterocycles* **1976**, *5*, 699. (b) Manhas, M.S.; Wagle, D.R.; Chiang, J.; Bose, A.K. *Heterocycles*, **1988**, *27*, 1755.
- 5 (a) Kagan, H.B.; Basselier, J.-J.; Luche, J.-L. *Tetrahedron Lett.* **1964**, 941. (b) Luche, J.-L.; Kagan, H.B. *Bull. Soc. Chim. Fr.* **1969**, 3500. (c) Luche, J.-L.; Kagan, H.B. *Bull. Soc. Chim. Fr.* **1971** 2260. (d) Dardoize, F.; Moreau, J.-L.; Gaudemar, M. *Bull. Soc. Chim. Fr.* **1973**, 1668. And Ref. therein cited.
- 6 Gluchowski, C.; Cooper, L.; Bergbreiter, D.E.; Newcomb, M. *J. Org. Chem.* **1980**, *45*, 3413.
- 7 (a) Andreoli, P.; Cainelli, G.; Contento, M.; Giacomini, D.; Martelli, G.; Panunzio, M. *Tetrahedron Lett.* **1986**, *27*, 1695. (b) Cainelli, G.; Giacomini, D.; Panunzio, M.; Martelli, G. Spunta, G. *Tetrahedron Lett.* **1987**, *27*, 5369. (c) Andreoli, P.; Cainelli, G.; Contento, M.; Giacomini, D.; Martelli, G.; Panunzio, M. *J. Chem. Soc. Perkin I*, **1988**, 945. (d) Guillermin, J.C.; Ammi, L.; Denis, J.M. *Tetrahedron Lett.* **1988**, *29*, 1287. (e) Uyehara, T.; Suzuki, I.; Yamamoto, Y. *Tetrahedron Lett.* **1989**, *30*, 4275.
- 8 (a) Ghosez, L.; Bogdan, S.; Ceresiat, M.; Frydrych, C.; Marchand-Brynaert, J.; Moya-Portuguez, M.; Hubert, I. *Pure Applied Chem.* **1987**, *59*, 393. (b) Marchand-Brynaert, J.; Moya-Portuguez, M.; Hubert, I.; Ghosez, L. *J. Chem. Soc., Chem. Commun.* **1983**, 818. (c) Belzecki, C.; Rogalska, E. *J. Chem. Soc., Chem. Commun.* **1981**, 57. (d) Rogalska, E.; Belzecki, C. *J. Org. Chem.* **1984**, *49*, 1397.
- 9 (a) Thomas, R.C. *Tetrahedron Lett.* **1989** *30*, 5239. (b) Teutsch, G.; Bennet, A. *Tetrahedron Lett.* **1984**, *25*, 1561. (c) Klich, M.; Teutsch, G. *Tetrahedron Lett.* **1986**, *42*, 2677. (d) Dugat, D.; Just, G.; Sahoo, S. *Can. J. Chem.* **1987**, *65*, 88. (e) Gunda, T.E.; Vieth, S.; Kovér, K.E.; Sztaricskai, F. *Tetrahedron Lett.* **1990**, *31*, 6707. (f) Aszodi, J.; Bonnet, A.; Teutsch, G.; *Tetrahedron Lett.* **1990**, *46*, 1579.
- 10 Furukawa, M.; Okawara, T.; Noguchi, Y.; Terawaki, Y.; *Chem. Pharm. Bull.* **1978**, *26*, 748.
- 11 Hart, D.J.; Lee, C.S.; Pirkle, W.H.; Hyon, M.H.; Tsiouras, A. *J. Am. Chem. Soc.* **1986**, *108*, 6054.
- 12 Oppolzer, W.; Chapuis, C.; Bernardinelli, G. *Tetrahedron Lett.* **1984**, *25*, 5885.
- 13 (a) Miller, R.W.J. *Nat. Prod.* **1980**, *43*, 425. (b) Wani, M.C.; Taylor, H.L.; Wall, M.E.; Coggon, P.; McPhail, A.T. *J. Am. Chem. Soc.* **1971**, *93*, 2325. (c) Gueritte-Voegelein, F.; Guenard, D.; Dubois, J.; Wahl, A.; Potier, P. *La Chimica e Industria*, **1994**, *76*, 490.
- 14 (a) Ojima, I.; Habus, I.; Zhao, M.; Zucco, M.; Park, H.Y.; Sun, M.C.; Brigaud, T. *Tetrahedron*, **1992**, *48*, 6985. (b) Georg, I.G.; Chervallath, S.Z.; Harriman, B.C.G.; Hepperle, M.; Park, H. *Bio. Med. Chem. Lett.* **1993**, *3*, 2467.
- 15 (a) Perrone, E. and Franceschi, G. in *Recent Progress in the Chemical Synthesis of Antibiotics* Lukacs, G. and Ohno, M. Eds; Springer-Verlag Berlin 1990, pag. 615-703. (b) Palomo, C. *ibid.* pp 565-612. (c) Nagahara, T.; Kametani, T. *Heterocycles* **1987**, *25*, 729. (d) Durckeimer, W.; Blumbach, J.; Lattrell, R.; Scheunemann, K.H. *Angew. Chem. Int. Ed. Engl.* **1985**, *24*, 180.
- 16 For a three component approach to chiral β -methyl carbapenem see: (a) Tsukada, N.; Shimada, T.; Gyoung, Y.S.; Asao, N.; Yamamoto, Y. *J. Org. Chem.* **1995**, *60*, 143. (b) Datta, A.; Georg, G.I. *Chem. Tracts*, **1995**, *7*, 306 and references therein cited.
- 17 (a) Chiba, T.; Nagatsuma, M.; Nakai, T. *Chem. Lett.* **1984**, 1927. (b) Chiba, T.; Nakai, T. *Chem. Lett.* **1985**, 651. (c) Chiba, T.; Nagatsuma, M.; Nakai, T. *Chem. Lett.* **1985**, 1343. (d) Chiba, T.; Nakai, T. *Tetrahedron Lett.* **1985**, *26*, 4647.
- 18 (a) Hart, D.J.; Kanai, K.; Thomas, D.G.; Yang, T.-K. *J. Org. Chem.* **1983**, *48*, 289. (b) Hart, D.J.; Ha, D.-C.; Yang, T.-K. *J. Am. Chem. Soc.* **1984**, *106*, 4819. (c) Hart, D.J.; Ha, D.-C. *Tetrahedron Lett.* **1985**, 5493.
- 19 (a) Georg, I.G.; *Tetrahedron Lett.* **1984**, *25*, 3779. (b) Georg, I.G.; Gill, H.S.; Gerhardt, C. *Tetrahedron Lett.* **1985**, *26*, 3903. (c) Georg, I.G.; Kant, J.; Gill, H.S. *J. Am. Chem. Soc.* **1987**, *109*, 1129. (d) Georg, I.G.; Akgun, E. *Tetrahedron Lett.* **1990**, *31*, 3267.
- 20 (a) Iimori, T.; Shibasaki, M. *Tetrahedron Lett.* **1985**, *26*, 1523. (b) Iimori, T.; Shibasaki, M. *Tetrahedron Lett.*, **1986**, *27*, 2149. (c) Iimori, T.; Ishida, Y.; Shibasaki, M. *Tetrahedron Lett.* **1986**, *27*, 2153. (d) Mori, M.; Kagechika, K.; Tohjma, K.; Shibasaki, M. *Tetrahedron Lett.* **1988**, *27*,
- 21 (a) Cainelli, G.; Panunzio, M.; Basile, T.; Bongini, A.; Giacomini, D.; Martelli, G. *J. Chem. Soc. Perkin I*, **1987**, 2637. (b) Cainelli, G.; Contento, M.; Giacomini, D.; Panunzio, M. *Tetrahedron Lett.*, **1985**, *26*, 937.
- 22 Reviews on monobactams: Cimarusti, C.M.; Sykes, R.B. *Chem. In Britain* **1983**, 302. Miller, M.J. *Acc. Chem. Res.* **1986**, *44*, 5553. Recent papers on the synthesis of monobactams: (a) Banfi, L.; Cascio, G.; Guanti, G.; Ghiron, C.; Manghisi, E.; Narisano, E.; Riva, R. *Tetrahedron*, **1995**, *50*, 11983 and Ref. cited. (b) Teng, M.; Miller, M.J. *J. Am. Chem. Soc.* **1993**, *115*, 548. (c) Brown, M.J.; Overman, L.E. *J. Org. Chem.* **1991**, *56*, 1933.
- 23 Furukawa, M.; Okawara, T.; Noguchi, Y.; Terawaki, Y. *Chem. Pharm. Bull.* **1978**, *26*, 260.
- 24 (a) Overman, L.E.; Brown, M.J. *J. Org. Chem.* **1991**, *56*, 1993. (b) Overman, L.E.; Osawa, T. *J. Am. Chem. Soc.* **1985**, *107*, 1698.
- 25 (a) Cainelli, G.; Panunzio, M.; Giacomini, D.; Martelli, G.; Spunta, G.; Bandini, E. NATO-ASI "Chemical Synthesis: Gnosis and Prognosis" 1995, In Press. (b) Cainelli, G.; Panunzio, M.; Bandini, E.; Martelli, G.; Spunta, G.; Da Col, M. *Tetrahedron* **1995**, *51*, 5067. (c) Panunzio, M.; Andreoli, P.;

- Martelli, G.; Spunta, G.; Giacomini, D.; Bandini, E. *Pure and Applied Chem.* **1990**, *62*, 605. (d) Panunzio, M.; Giacomini, D.; Bandini, E. *Seminars in Organic Synthesis S.C.I* (c) Bandini, E.; Cainelli, G.; Giacomini, D.; Martelli, G.; Panunzio, M.; Spunta, G. *Biorganic and Medicinal Chem. Lett.* **1993**, *3*, 2347. (f) Bandini, E.; Cainelli, G.; Giacomini, D.; Martelli, G.; Panunzio, M.; Spunta, G. *Gazz. Chim. It.* **1993**, *123*, 509. (g) Andreoli, P.; Cainelli, G.; Panunzio, M.; Bandini, E.; Martelli, G.; Spunta, G. *J. Org. Chem.*, **1991**, *56*, 5984. (h) Andreoli, P.; Billi, L.; Cainelli, G.; Panunzio, M.; Bandini, E.; Martelli, G.; Spunta, G. *Tetrahedron.* **1991**, *47*, 9061. (i) Cainelli, G.; Panunzio, M. *Il Farmaco*, **1991**, *46*, 177. (j) Cainelli, G.; Panunzio, M.; Giacomini, D.; Martelli, G.; Spunta, G. *J. Am. Chem. Soc.* **1988**, *110*, 6879
- 26 Bernardi, F.; Bongini, A.; Cainelli, G.; Robb, M.A.; Suzzi Valli, G. *J. Org. Chem.* **1993**, *58*, 750.
- 27 Bongini, A.; Giacomini, D.; Panunzio, M.; Suzzi-Valli, G.; Zarantonello, P. *Spectrochimica Acta* **1995**, *51A*, 563.
- 28 Although we consider it unlikely under the reaction conditions used, reversible addition of Reformasky reagents to imines has been clearly established: (a) Dardoize, F.; Gaudemar, M. *Bull. Soc. Chim. Fr.* **1974**, 939. See also Ref. 5.
- 29 For an excellent discussion of the possible transition state of ester-enolate-imine condensation see: Evans, D.A.; Nelson, J.V.; Taber, T.R.; *Topics in Stereochemistry*; Allinger, N.L., Eliel, E.L., S.H., Eds.; Wiley: New York, 1982; Vol. 13, pp 1-117
- 30 (a) Ireland, R.E.; Mueller, R.H.; Willard, A.K. *J. Am. Chem. Soc.* **1976**, *98*, 2868. (b) Heathcook, C.H.; Buse, C.T.; Kleschick, W.A.; Pirrung, M.C.; Sohn, J.E.; Lampe, J. *J. Org. Chem.* **1980**, *45*, 1066. (c) Seebach, D.; Armstutz, R.; Laube, T.; Schweizer, B.; Dunitz, J.D. *J. Am. Chem. Soc.* **1985**, *107*, 5403. (d) van der Steen, F.H.; Boersma, J.; Spek, A.L.; van Koten, G. *J. Organomet. Chem.* **1990**, *390*, C21. (e) van der Steen, F.H.; Boersma, J.; Spek, A.L.; van Koten, G. *Organometallics* **1991**, *10*, 2467.
- 31 The reaction of the zinc enolates have been extensively studied by van Koten *et al.*, e.g., (a) van Maanen, H.L.; Kleijn, H.; Jastrzebski, J.T.B.H.; Lakin, M.T.; Spek, A.L.; van Koten, G. *J. Org. Chem.* **1994**, *59*, 7839. (b) van der Steen, F.H.; Kleijn, H.H.; Jastrzebski, J.T.B.H.; van Koten, G. *J. Org. Chem.* **1991**, *56*, 5147. (c) van der Steen, F.H.; Kleijn, H.; Spek, A.L.; van Koten, G. *J. Org. Chem.* **1991**, *56*, 5868. The reaction of titanium enolates and thioesters has been elegantly developed by Cinquini, M. and Cozzi, F. See for example: (a) Annunziata, R.; Benaglia, M.; Cinquini, M.; Cozzi, F.; Raimondi, L. *Tetrahedron*, **1994**, *50*, 9471.
- 32 The generation of the imine by means of NaHMDSA gives rise to a diastereoselection comparable with that found using LiHMDSA. Nevertheless a faster imine formation and better yields in azetidinones are obtained with the latter one.
- 33 For simplicity sake only one enantiomer has been reported.
- 34 STABASE as protecting group: Djuric, S.; Venit, J.; Magnus, P. *Tetrahedron Lett.* **1981**, *22*, 1787.
- 35 See for example: Descases, J.; Luche, J.L.; Kagan, H.B. *Tetrahedron Lett.* **1975**, 3661.
- 36 Reetz, M.T. *Angew. Chem. Int. Ed. Engl.* **1984**, *23*, 556.
- 37 Concerning the influence of temperature and solvent on nucleophilic addition to *N*-(trimethylsilyl)imine of (2*S*)-lactal see: Cainelli, G.; Giacomini, D.; Walzl, M. *Angew. Chem. Int. Ed.* **1995**, 000. German Version: *Angew. Chem.* **1995**, *107*, 000.
- 38 Shambayati, S.; Blake, F.J.; Wierschke, G.S.; Jorgensen, L.W.; Schreiber, L.S. *J. Am. Chem. Soc.* **1990**, *112*, 697.3,279-3,267*300=
- 39 (a) Chen, X.; Hortelano, E.R.; Eliel, E.L. *J. Am. Chem. Soc.* **1990**, *112*, 6130. (b) Chen, X.; Hortelano, E.R.; Eliel, E.L.; Frye, S.V. *J. Am. Chem. Soc.* **1992**, *114*, 1778. For a up-to-date discussion on chelation controlled carbonyl addition see: Mori, S.; Nakamura, E.; Nakamura, M.; Koga, N.; Morokuma, K. *J. Am. Chem. Soc.* **1995**, *117*, 5055.
- 40 Leitereg, T. J.; Cram, D. J. *J. Am. Chem. Soc.* **1968**, *90*, 4019
- 41 The spectral data of the compounds **16c**, **18c**, **19c** were superimposable with those of enantiomeric compounds **16b**, **18b**, and **19b** (see Ref. 25f)

(Received in UK 16 October 1995; revised 6 November 1995; accepted 9 November 1995)